---
company: DataMeds AI, Inc.
ticker: MEDS
form: 8-K
filed: 2026-08-18
accession: 0001493152-26-038891
source: https://www.sec.gov/Archives/edgar/data/2030763/000149315226038891/
---

# DataMeds AI (MEDS) earnings release, August 18, 2026

DataMeds AI, Inc. (MEDS) · Form 8-K, Item 2.02 · Filed 2026-08-18 · [SEC filing](https://www.sec.gov/Archives/edgar/data/2030763/000149315226038891/)

DataMeds

AI Reports Second Quarter 2026 Financials and Provides Business Update

Tampa,

Fla. / August 17, 2026 / DataMeds AI, Inc. (NASDAQ: MEDS) (“DataMeds AI,” “DataMEDS,” or the “Company”), an integrated healthcare company leveraging its Health IT infrastructure and artificial intelligence platform EinsteinRx™ combined with blockchain-enabled smart contracts platform PharmacyChain™ to provide integrated solutions for the compliant delivery of healthcare and monetization of health data by market participants, today reported second quarter 2026 financials and provided a business update.

The Company is expecting to launch the Health Lives Here (HLH) consumer app together with National Football League Alumni Health (NFLAH) in September 2026, targeting patients on or contemplating taking GLP-1 agonist medications in rural communities through their local independent pharmacies. The Company recently made available companion medical food Forzet, indicated for the dietary management of muscle associated with weight loss therapies, through its pharmacy-focused division Corexa Health (dba Corexa Health AI, www.corexahealthai.com).

“Having been in leadership now for just under three months, I am excited with the significant progress we are making towards the important milestone of launching the Health Lives Here app together with NFLAH,” said Gerald Commissiong, interim co-CEO of DataMEDS. “As we move towards this important milestone, we have successfully begun consolidating the key healthcare infrastructure needed to deliver a workflow for the patient that will result in a seamless patient experience that will allow patients to engage with their healthcare in a way that was previously not possible. We intend to engage the patient through telemedicine, a consumer app and their local independent pharmacist who will be educated on the pharmaceutical-adjunct products we provide through our relationship with Tollo Health that are intended to help mitigate drugs’ side effects and improve their effectiveness at the initial HLH app launch. As previously stated, we intend to acquire a CLIA lab that will allow us to offer direct-to-consumer testing, adding an additional layer of service for patients while allowing us to further integrate our customers’ healthcare data into their patient profiles that patients will be able to

‘opt-in’ to be fed into our EinsteinRx artificial intelligence platform to gain unique healthcare insights, including wearables data correlated with pharmacodynamic drug response. Ultimately we intend to move all of this data onto the blockchain, protected through our Datavault AI (NASDAQ: DVLT) license that provides us with patent protection on healthcare data tokenization and monetization, allowing us to provide patients with an opportunity to participate in the revenue generated through the sale of their health data.

We also intend to perfect intended launch of a drone service to deliver medical products, with biometric confirmation of delivery through

QOLPOM patents being acquired from Scilex Holdings (NASDAQ: SCLX) and EOS Technology Holdings. The first medical products drone service in the United States was recently completed by Cleveland Clinic, although this service does not include biometric confirmation of who the medications are being delivered to.

Second

Quarter 2026 Corporate Highlights

Third

Quarter 2026 Highlights to Date

Expected

Remaining Second Half 2026 Milestones

Loss from Operations:

The

Company recorded a net operating loss of $18.363 million in the quarter ended June 30, 2026, compared with a net operating loss of $6.672 million in the quarter ended June 30, 2025. The increase in net loss was largely due to the expenses associated with the extinguishment of debt and general and administrative expenses. Net loss per share in the quarter ended June 30, 2026 was $7.13 on 2.574 million weighted average shares outstanding, compared to the quarter ended June 30, 2025, where the Company delivered a loss of $5.50 per share on 1.235 million weighted average shares outstanding.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities.

For more information on DataMeds Ai, Inc., refer to www.datamedsai.com

About

DataMeds AI, Inc.

DataMeds

AI, Inc. (formerly Wellgistics Health) is a leading Health IT company that focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units to deliver a better healthcare experience for consumers. Headquartered in Tampa,

Fla., DataMeds AI incorporates the artificial intelligence platform EinsteinRx™ and blockchain-enabled smart contracts platform

PharmacyChain™ into the Health Lives Here mobile application, and its Corexa Health subsidiary provides pharmacy and pharmacy services, including the distribution of products developed by Tollo Health, LLC.

Forward-Looking

Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, statements regarding: future events, including DataMeds AI, Inc.’s payment of the Dream

Bowl Tokens and the timing thereof (including that the Board may change the Payment Date) and the Company’s intention to deliver liquidity and broad distribution of the Dream Bowl Tokens. These statements are based on management’s current expectations and are not predictions of actual performance.; the Company’s plans to expand into telemedicine and diagnostic laboratory services; the Company’s proposed transaction with DataVault AI Inc., Scilex Holding Company, EOS Holdings and HealthBridge Advisors; the satisfaction or waiver of closing conditions applicable to any of the foregoing; the receipt of stockholder approval and any other required... (truncated)d business strategy, operating plans and growth opportunities; the integration of telemedicine, pharmacy, laboratory, wearable-device, artificial intelligence, blockchain and data-management technologies; the proposed development, commercialization and expansion of EinsteinRx AI, PharmacyChain, Health Lives Here and related platforms; the anticipated growth of the market for Long COVID products and related treatment approaches; the Company’s ability to empower patients to access, manage, control or monetize health data; the anticipated benefits of the Company’s technology platforms, strategic relationships and business combinations; the Company’s capitalization, outstanding securities, lock-up arrangements, public float and registration statements; the Company’s ability to maintain compliance with Nasdaq listing standards; and the Company’s liquidity, capital resources and ability to fund operations.

Forward-looking statements speak only as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

DataMeds

AI Media Contact

James

Lambert, Vice President

Rubenstein

Public Relations

Phone:

212.805.3024

Email: jlambert@rubensteinpr.com

DataMeds

AI Investor Contact

Investor

Relations:

IR@wellgisticshealth.com

PART

I—FINANCIAL INFORMATION

Item

1. Financial Statements.

DATAMEDS

AI, INC.

## Financial statements

### Income Statement (Three Months Ended — (Unaudited))

| | Three Months Ended – June 30, – 2026 | Three Months Ended – June 30, – 2025 | Six Months Ended – June 30, – 2026 | Six Months Ended – June 30, – 2025 |
|---|---:|---:|---:|---:|
| Net revenues | 1,779,860 | 7,790,865 | 3,339,423 | 18,654,308 |
| Cost of net revenues | 1,597,656 | 7,285,113 | 2,986,998 | 17,455,915 |
| Gross profit | 182,204 | 505,752 | 352,425 | 1,198,393 |
| Operating expenses: | General and administrative | 7,056,671 | 4,859,949 | 11,925,606 | 36,032,869 |
| Operating expenses: | Sales and marketing | 113,990 | 343,383 | 1,073,990 | 408,600 |
| Operating expenses: | Depreciation and amortization | 356,597 | 802,796 | 713,421 | 1,605,668 |
| Operating expenses: | Total operating expenses | 7,527,258 | 6,006,128 | 13,713,017 | 38,047,137 |
| Operating expenses: | Loss from operations | -7,345,054 | -5,500,376 | -13,360,592 | -36,848,744 |
| Other income/(expense): | Interest expense, net | -1,561,240 | -1,184,040 | -3,633,919 | -2,278,530 |
| Other income/(expense): | Loss on extinguishment of vendor obligation | -320,000 |  | -60,120 |  |
| Other income/(expense): | Loss on extinguishment of debt | -8,881,694 |  | -8,881,694 |  |
| Other income/(expense): | Loss on contract termination fee | -766,394 |  | -766,394 |  |
| Other income/(expense): | Settlement fees |  |  | -13,000 |  |
| Other income/(expense): | Other income | 511,157 | 11,952 | 609,897 | 23,907 |
| Other income/(expense): | Total other expense, net | -11,018,171 | -1,172,088 | -12,745,230 | -2,254,623 |
| Other income/(expense): | Net loss before income taxes | -18,363,225 | -6,672,464 | -26,105,822 | -39,103,367 |
| Provision for income taxes | Net loss | -18,363,225 | -6,672,464 | -26,105,822 | -39,103,367 |
| Provision for income taxes | Weighted average common shares outstanding - basic and diluted | 2,574,669 | 1,235,423 | 2,335,557 | 1,137,274 |
| Provision for income taxes | Net loss per common share - basic and diluted | -7.13 | -5.4 | -11.18 | -34.38 |

### Balance Sheet (December 31, — (Unaudited))

| | June 30, – 2026 – (Unaudited) | December 31, – 2025 |
|---|---:|---:|
| Current assets: | Cash and cash equivalents | 2,456,373 | 42,571 |
| Current assets: | Accounts receivable, net | 1,174,336 | 1,137,219 |
| Current assets: | Inventories, net | 1,510,123 | 1,639,426 |
| Current assets: | Due from related party | 26,068 |  |
| Current assets: | Prepaid and other current assets | 465,738 |  |
| Current assets: | Total current assets | 5,632,638 | 2,819,216 |
| Current assets: | Property, plant and equipment, net | 173,879 | 229,376 |
| Current assets: | Capitalized software | 2,297,588 | 1,850,358 |
| Current assets: | Operating lease, right-of-use-assets | 719,645 | 966,893 |
| Current assets: | Goodwill | 14,193,923 | 14,193,923 |
| Current assets: | Other intangible assets, net | 9,656,751 | 10,314,675 |
| Current assets: | Deposits | 85,008 | 85,008 |
| Current assets: | Total assets | 32,759,432 | 30,459,449 |
| Current liabilities: | Accounts payable | 12,612,167 | 11,665,135 |
| Current liabilities: | Accounts payable, related party | 25,500 | 25,500 |
| Current liabilities: | Accrued expenses and other liabilities | 7,003,749 | 6,407,722 |
| Current liabilities: | Due to related parties |  | 225,000 |
| Current liabilities: | Convertible notes payable, net of debt discount | 12,101,803 |  |
| Current liabilities: | Current portion of debt obligations, net of debt discount | 7,104,225 | 10,887,520 |
| Current liabilities: | Operating lease liabilities- current portion | 566,379 | 569,251 |
| Current liabilities: | Total current liabilities | 39,413,823 | 29,780,128 |
| Current liabilities: | Notes payable | 12,600,000 | 12,600,000 |
| Current liabilities: | Operating lease liabilities | 249,840 | 527,122 |
| Current liabilities: | Total liabilities | 52,263,663 | 42,907,250 |
| Stockholders’ equity (deficit): | Common stock, $0.0001 par value, 500,000,000 shares authorized, 2,847,198 and 2,045,792 shares issued and 2,836,484 and 2,026,150 shares outstanding as of June 30, 2026 and December 31, 2025, respectively | 283 | 203 |
| Stockholders’ equity (deficit): | Additional paid-in capital | 117,632,998 | 98,583,686 |
| Stockholders’ equity (deficit): | Accumulated deficit | -137,137,512 | -111,031,690 |
| Stockholders’ equity (deficit): | Total stockholders’ equity (deficit) | -19,504,231 | -12,447,801 |
| Stockholders’ equity (deficit): | Total liabilities and stockholders’ equity (deficit) | 32,759,432 | 30,459,449 |
